Walk On! Physical Activity Coaching

February 7, 2020 updated by: Huong Q2 Nguyen, Kaiser Permanente

Patient-Centered Physical Activity Coaching in COPD: A Pragmatic Trial

Chronic obstructive pulmonary disease (COPD) is the third leading cause of the death in the US. The personal, social and economic costs of the disease are tremendous, with annual expenditures of nearly $50 billion, mostly from hospitalizations for exacerbations of COPD and associated sequelae. For the vast majority of patients, despite optimal pharmacological therapy, living with COPD is characterized by unrelieved dyspnea, physical inactivity, deconditioning, and an insidious downward spiral of social isolation and depression that has a profound impact on the lives of patients and their caregivers. There is mounting evidence that physical inactivity is significantly associated with more frequent hospitalizations and increased mortality in COPD even after adjusting for disease severity.

While practice guidelines recommend regular physical activity for all patients with COPD, health systems are challenged in operationalizing an effective and sustainable approach to assist patients in being physically active. The investigators propose a pragmatic randomized controlled trial to determine the effectiveness of a 12-month physical activity coaching intervention (Walk On!) compared to standard care for 1,650 COPD patients from a large integrated health care system.

Study Overview

Detailed Description

Physical inactivity is significantly associated with more frequent hospitalizations and increased mortality in COPD even after adjusting for disease severity. While practice guidelines recommend regular physical activity for all patients with COPD, health systems are challenged in operationalizing an effective and sustainable approach to assist patients in being physically active.

A pragmatic randomized controlled trial design will be used to determine the effectiveness of a 12-month home and community-based physical activity coaching intervention (Walk On!) compared to standard care for 2,700 COPD patients from a large integrated health care system. Eligible patients with a COPD-related hospitalization, emergency department visit, or observational stay in the previous 12 months will be automatically identified from the electronic medical records (EMR) system and randomized to treatment arms. The Walk On! intervention includes collaborative monitoring of step counts, semi-automated step goal recommendations, individualized reinforcement from a physical activity coach, and peer/family support.

The primary composite outcome includes all-cause hospitalizations, emergency department visits, observational stays, and death in the 12 months following randomization. Secondary outcomes include COPD-related utilization, cardio-metabolic markers, physical activity, symptoms, and health-related quality of life. With the exception of patient reported outcomes, all utilization and clinical variables will be automatically captured from the EMR.

If successful, findings from this multi-stakeholder driven trial of a generalizable and scalable physical activity intervention model, carefully designed with sufficient flexibility, intensity, duration, and support for a large ethnically diverse sample could re-define the standard of care to effectively address physical inactivity in COPD.

Study Type

Interventional

Enrollment (Actual)

2707

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Pasadena, California, United States, 91101
        • Kaiser Permanente Southern California

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

41 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients with any COPD-related hospitalization, emergency department visit or observational stay in the previous 12 months are eligible for the study. COPD-related encounters are defined according to the Centers for Medicare and Medicaid Services (CMS) and National Quality Forum (NQF) criteria for the Hospital Readmission Reduction Program. The following principal discharge diagnoses of COPD (ICD-9 codes: 491.21, 491.22, 491.8, 491.9, 492.8, 493.20, 493.21, 493.22, and 496) or respiratory failure (ICD-9 codes: 518.81, 518.82, 518.84, 799.1) with a secondary diagnosis of COPD exacerbation (ICD-9 codes: 491.21, 491.22, 493.21, 493.22) will be used
  • Age >40 years
  • On at least a bronchodilator or steroid inhaler prior to the encounter or if not on an inhaler, had a previous COPD diagnosis
  • Continuous health plan membership in the 12 months prior to the encounter

Exclusion Criteria:

  • FEV1/FVC ratio >0.70 at any point in the past year for those with spirometry data
  • Discharged to hospice, a skilled nursing facility, long term-care or another acute care hospital during the index admission
  • Level of function at admission or discharge during the index admission is bed bound
  • Has Alzheimers disease, dementia or metastatic cancer
  • Morbidly obese (BMI >40)
  • Completed pulmonary rehabilitation in the last 6 months
  • Deceased
  • Dis-enrolled from the health plan

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Standard Care
Standard care patients received their routine care from Kaiser Permanente Southern California and had access to all health services in accordance with their health plan
Experimental: Physical Activity Coaching (Walk On!)
The 12-month Walk On! intervention included a baseline in-person assessment, collaborative monitoring of steps using two types of activity sensors, semi-automated step goal recommendations using an interactive voice response system or web application, ongoing individualized reinforcement from a physical activity coach, and peer/family support.
The 12-month Walk On! intervention included a baseline in-person assessment, collaborative monitoring of steps using two types of activity sensors, semi-automated step goal recommendations using an interactive voice response system or web application, ongoing individualized reinforcement from a physical activity coach, and peer/family support.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants With All-cause Hospitalizations, Emergency Department (ED) Visits, Observation Stays, and Deaths
Time Frame: 12 months following randomization
Covariates included in the adjusted multivariate models were age, FEV1% predicted, Charlson comorbidity index, oxygen use, hospitalization for COPD in previous 12 months, outpatient treated COPD exacerbation in previous 12 months, length of time since acute care utilization to randomization, use of LABA or ICS, PA level and study site
12 months following randomization

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Deaths Among Participants
Time Frame: 12 months following randomization
Covariates included in the adjusted multivariate models were age, FEV1% predicted, Charlson comorbidity index, oxygen use, hospitalization for COPD in previous 12 months, outpatient treated COPD exacerbation in previous 12 months, length of time since acute care utilization to randomization, use of LABA or ICS, PA level and study site
12 months following randomization
Number of Participants With All-cause Hospitalizations
Time Frame: 12 months following randomization
Covariates included in the adjusted multivariate models were age, FEV1% predicted, Charlson comorbidity index, oxygen use, hospitalization for COPD in previous 12 months, outpatient treated COPD exacerbation in previous 12 months, length of time since acute care utilization to randomization, use of LABA or ICS, PA level and study site
12 months following randomization
Number of Participants With All-cause Emergency Department Visits
Time Frame: 12 months following randomization
Covariates included in the adjusted multivariate models were age, FEV1% predicted, Charlson comorbidity index, oxygen use, hospitalization for COPD in previous 12 months, outpatient treated COPD exacerbation in previous 12 months, length of time since acute care utilization to randomization, use of LABA or ICS, PA level and study site
12 months following randomization
Number of Participants With All-cause Observation Stays
Time Frame: 12 months following randomization
Covariates included in the adjusted multivariate models were age, FEV1% predicted, Charlson comorbidity index, oxygen use, hospitalization for COPD in previous 12 months, outpatient treated COPD exacerbation in previous 12 months, length of time since acute care utilization to randomization, use of LABA or ICS, PA level and study site
12 months following randomization
Number of Participants With COPD-Related Hospitalizations, ED Visits, and Observation Stays
Time Frame: 12 months following randomization
Covariates included in the adjusted multivariate models were age, FEV1% predicted, Charlson comorbidity index, oxygen use, hospitalization for COPD in previous 12 months, outpatient treated COPD exacerbation in previous 12 months, length of time since acute care utilization to randomization, use of LABA or ICS, PA level and study site
12 months following randomization
Number of Participants With COPD Exacerbation
Time Frame: 12 months following randomization
COPD exacerbations were ascertained via pharmacy records and utilization data. An outpatient COPD exacerbation will be defined as a care touch (clinic visit, phone, or secure message encounter) with a diagnosis of COPD accompanied by a prescription of either an oral steroid or an antibiotic within 2 days
12 months following randomization
COPD Assessment Test, CAT - 12 Months
Time Frame: 12 months
The reported mean change between the baseline and 12 Months scores for the Chronic Obstructive Pulmonary Disease Assessment Test (CAT). Score range is 0-40. A negative change score indicates fewer symptoms.
12 months
Physical Activity
Time Frame: 12 months
Patients were categorized as being: completely inactive (0 mins/week), insufficiently active (1-149 mins/week) or active, meeting national physical activity recommendations (>150 mins/week) of moderate to vigorous physical activity.
12 months
Personal Health Questionnaire, PHQ8 - 12 Months
Time Frame: 12 months
The reported mean change between the baseline and 12 Months scores. Score range is 0-24. A negative change score indicates less depressive symptoms.
12 months
General Anxiety Disorder, GAD-7 - 12 Months
Time Frame: 12 months
The reported mean change between the baseline and 12 Months scores. Score range is 0-21. A negative change score indicates less anxiety.
12 months
PROMIS-10 HRQL , Physical Health - 12 Months
Time Frame: 12 months
The reported mean change between the baseline and 12 Months T-scores. Score range is 16-68. A positive change score reflects better physical functioning.
12 months
PROMIS-10 HRQL , Mental Health - 12 Months
Time Frame: 12 months
The reported mean change between the baseline and 12 Months T-scores. Score range is 21-68. A positive change score reflects better mental health.
12 months
Diastolic Blood Pressure
Time Frame: 12 months following randomization
Average of all routine clinic blood pressure reading taken between 6 and 12-months post randomization. BP obtained with temperatures of >100F and those obtained in urgent care were excluded.
12 months following randomization
Systolic Blood Pressure
Time Frame: 12 months following randomization
Average of all routine clinic blood pressure reading taken between 6 and 12-months post randomization. BP obtained with temperatures of >100F and those obtained in urgent care were excluded.
12 months following randomization
HbA1c Levels
Time Frame: 12 months following randomization
HbA1c levels were obtained only from diabetics and on values closest to the 12 months post randomization
12 months following randomization
LDL Levels
Time Frame: 12 months following randomization
Cholesterol levels were obtained from values closest to the 12 months post randomization
12 months following randomization
HDL Levels
Time Frame: 12 months following randomization
Cholesterol levels were obtained from values closest to the 12 months post randomization
12 months following randomization
Total Cholesterol Levels
Time Frame: 12 months following randomization
Cholesterol levels were obtained from values closest to the 12 months post randomization
12 months following randomization
Triglycerides Levels
Time Frame: 12 months post randomization
Cholesterol levels were obtained from values closest to the 12 months post randomization
12 months post randomization
Body Mass Index
Time Frame: 12 months following randomization
Body mass index measurements were based on values closest to the 12 months post randomization
12 months following randomization

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants With All-cause Hospitalization, Emergency Department (ED) Visits, Observation Stays and Deaths
Time Frame: 2 to 12 months following randomization
As-treated analyses using logistic regression models that included stabilized propensity score inverse probability of treatment weighting (IPTW) to balance baseline characteristics (socio-demographics, health behaviors, disease severity, comorbidities, inhalers/medications, and health care utilization in the prior year) between patients who participated in Walk On! intervention and the SC group. The first 2 months after randomization were excluded because it was expected that it would take approximately 2 months form the date of randomization to start the intervention.
2 to 12 months following randomization
Number of Deaths Among Participants
Time Frame: 2 to 12 months following randomization
As-treated analyses using logistic regression models that included stabilized propensity score inverse probability of treatment weighting (IPTW) to balance baseline characteristics (socio-demographics, health behaviors, disease severity, comorbidities, inhalers/medications, and health care utilization in the prior year) between patients who participated in Walk On! intervention and the SC group. The first 2 months after randomization were excluded because it was expected that it would take approximately 2 months form the date of randomization to start the intervention.
2 to 12 months following randomization
Number of Participants With All-cause Hospitalizations
Time Frame: 2 to 12 months following randomization
As-treated analyses using logistic regression models that included stabilized propensity score inverse probability of treatment weighting (IPTW) to balance baseline characteristics (socio-demographics, health behaviors, disease severity, comorbidities, inhalers/medications, and health care utilization in the prior year) between patients who participated in Walk On! intervention and the SC group. The first 2 months after randomization were excluded because it was expected that it would take approximately 2 months form the date of randomization to start the intervention.
2 to 12 months following randomization
Number of Participants With All-cause Emergency Department Visits
Time Frame: 2 to 12 months following randomization
As-treated analyses using logistic regression models that included stabilized propensity score inverse probability of treatment weighting (IPTW) to balance baseline characteristics (socio-demographics, health behaviors, disease severity, comorbidities, inhalers/medications, and health care utilization in the prior year) between patients who participated in Walk On! intervention and the SC group. The first 2 months after randomization were excluded because it was expected that it would take approximately 2 months form the date of randomization to start the intervention.
2 to 12 months following randomization
Number of Participants With All-cause Observation Stays
Time Frame: 2 to 12 months following randomization
As-treated analyses using logistic regression models that included stabilized propensity score inverse probability of treatment weighting (IPTW) to balance baseline characteristics (socio-demographics, health behaviors, disease severity, comorbidities, inhalers/medications, and health care utilization in the prior year) between patients who participated in Walk On! intervention and the SC group. The first 2 months after randomization were excluded because it was expected that it would take approximately 2 months form the date of randomization to start the intervention.
2 to 12 months following randomization
Number of Participants With COPD-Related Hospitalizations, ED Visits, and Observation Stays
Time Frame: 2 to 12 months randomization
As-treated analyses using logistic regression models that included stabilized propensity score inverse probability of treatment weighting (IPTW) to balance baseline characteristics (socio-demographics, health behaviors, disease severity, comorbidities, inhalers/medications, and health care utilization in the prior year) between patients who participated in Walk On! intervention and the SC group. The first 2 months after randomization were excluded because it was expected that it would take approximately 2 months form the date of randomization to start the intervention.
2 to 12 months randomization
Diastolic Blood Pressure
Time Frame: 6-12 months following randomization
Average of all routine clinic blood pressure reading taken between 6 and 12-months post randomization. BP obtained with temperatures of >100F and those obtained in urgent care were excluded.
6-12 months following randomization
Systolic Blood Pressure
Time Frame: 6-12 months following randomization
Average of all routine clinic blood pressure reading taken between 6 and 12-months post randomization. BP obtained with temperatures of >100F and those obtained in urgent care were excluded.
6-12 months following randomization
HbA1c Levels
Time Frame: 12 months
HbA1c levels were obtained only from diabetics and on values closest to the 12 months post randomization
12 months
LDL Levels
Time Frame: 12 months
Cholesterol levels were obtained from values closest to the 12 months post randomization
12 months
HDL Levels
Time Frame: 12 months
Cholesterol levels were obtained from values closest to the 12 months post randomization
12 months
Total Cholesterol Levels
Time Frame: 12 months
Cholesterol levels were obtained from values closest to the 12 months post randomization
12 months
Triglycerides Levels
Time Frame: 12 months
Cholesterol levels were obtained from values closest to the 12 months post randomization
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Huong Q Nguyen, PhD, RN, Research Scientist

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2015

Primary Completion (Actual)

August 1, 2018

Study Completion (Actual)

December 1, 2018

Study Registration Dates

First Submitted

June 3, 2015

First Submitted That Met QC Criteria

June 18, 2015

First Posted (Estimate)

June 23, 2015

Study Record Updates

Last Update Posted (Actual)

February 19, 2020

Last Update Submitted That Met QC Criteria

February 7, 2020

Last Verified

February 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • KPSC IRB 12345

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Obstructive Pulmonary Disease (COPD)

Clinical Trials on Physical Activity Coaching (Walk On!)

Subscribe